Advertisement
week in cancer news
  • April 28: The Week in Cancer News

    More programs address sexual health in cancer survivors, and survey suggests health insurance often doesn’t cover genetic tumor testing.

    by Marci A. Landsmann

  • April 21: The Week in Cancer News

    Awareness of HPV link to cancer has declined, and more frequent COVID-19 boosters authorized for people who are immunocompromised.

    by Eric Fitzsimmons

  • April 14: The Week in Cancer News

    Treatment vaccines are on the horizon, and immunotherapy drugs are effective in treating multiple myeloma.

    by Kevin McLaughlin

  • April 7: The Week in Cancer News

    New therapy approved for locally advanced or metastatic bladder cancer, and court ruling could lead to cost hikes for certain cancer screenings.

    by Thomas Celona

  • March 31: The Week in Cancer News

    Immunotherapies poised to change care in advanced endometrial cancer, and the end of pandemic protection expected to result in loss of health coverage for 15 million people.

    by Eric Fitzsimmons

  • March 24: The Week in Cancer News

    Drug shortage affects patients with advanced prostate cancer, and military pilots and ground crews have increased cancer rates.

    by Marci A. Landsmann

  • March 17: The Week in Cancer News

    Active monitoring a viable choice for some with prostate cancer, and cancer’s effects on women’s sexual activity not addressed by providers.

    by Kevin McLaughlin

  • March 10: The Week in Cancer News

    The FDA sets rule that requires mammography providers to notify women who have dense breasts, and the ‘Jimmy Carter effect’ on immunotherapy treatment.

    by Eric Fitzsimmons

  • March 3: The Week in Cancer News

    Exercising only 11 minutes per day can reduce your cancer risk, and new robotic technology helps detect early-stage lung cancer.

    by Thomas Celona

  • February 24: The Week in Cancer News

    Aggressive end-of-life measures are common in people with advanced cancer in nursing homes, and findings suggest immune checkpoint inhibitors could one day be the preferred treatment in localized cancer.

    by Marci A. Landsmann